BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuang FL, De Melo MS, Makiya M, Kumar S, Brown T, Wetzler L, Ware JM, Khoury P, Collins MH, Quezado M, Pittaluga S, Klion AD. Benralizumab Completely Depletes Gastrointestinal Tissue Eosinophils and Improves Symptoms in Eosinophilic Gastrointestinal Disease. The Journal of Allergy and Clinical Immunology: In Practice 2022;10:1598-1605.e2. [DOI: 10.1016/j.jaip.2022.02.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Sindher SB, Barshow S, Tirumalasetty J, Arasi S, Atkins D, Bauer M, Bégin P, Collins MH, Deschildre A, Doyle AD, Fiocchi A, Furuta GT, Garcia-Lloret M, Mennini M, Rothenberg ME, Spergel JM, Wang J, Wood RA, Wright BL, Zuberbier T, Chin AR, Long A, Nadeau KC, Chinthrajah RS. The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders. J Allergy Clin Immunol 2023;151:595-606. [PMID: 36872039 DOI: 10.1016/j.jaci.2023.01.007] [Reference Citation Analysis]
2 Arakawa N, Yagi H, Shimizu M, Shigeta D, Shimizu A, Nomura S, Takizawa T, Yamada Y. Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders. Biomolecules 2023;13. [PMID: 36671497 DOI: 10.3390/biom13010112] [Reference Citation Analysis]
3 Nhu QM, Aceves SS. Current state of biologics in treating eosinophilic esophagitis. Ann Allergy Asthma Immunol 2023;130:15-20. [PMID: 36243282 DOI: 10.1016/j.anai.2022.10.004] [Reference Citation Analysis]
4 Jackson DJ, Pavord ID. Living without eosinophils: evidence from mouse and man. Eur Respir J 2023;61. [PMID: 35953100 DOI: 10.1183/13993003.01217-2022] [Reference Citation Analysis]
5 Turner PJ, Tang MLK, Wood RA. Food Allergy and Eosinophilic Gastrointestinal Diseases-The Next 10 Years. J Allergy Clin Immunol Pract 2023;11:72-8. [PMID: 36371062 DOI: 10.1016/j.jaip.2022.10.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Bagnasco D, Canevari RF, Passalacqua G, Caminati M. The new indications for biologicals in type 2 diseases: perspectives. Curr Opin Allergy Clin Immunol 2022;22:402-8. [PMID: 36165457 DOI: 10.1097/ACI.0000000000000862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Pesek RD, Gupta SK. Is clinical trial data showing positive progress for the treatment of eosinophilic esophagitis? Expert Opin Emerg Drugs 2022;27:225-7. [PMID: 36258645 DOI: 10.1080/14728214.2022.2136164] [Reference Citation Analysis]
8 Gleich GJ, Leiferman KM. Does Eosinophil Depletion in Gastroenteric Diseases Associated With the Hypereosinophilic Syndrome Teach Us Whether Normal Humans Need Eosinophils in 2022? The Journal of Allergy and Clinical Immunology: In Practice 2022;10:1606-1607. [DOI: 10.1016/j.jaip.2022.04.007] [Reference Citation Analysis]